Candel Therapeutics Inc. Insider Trading
CADL
Insiders bought $3M and sold $3.55M on the open market.
All of the selling was scheduled in advance under 10b5-1 plans.
Get an email when CADL's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Sep 10 – 11 | Paul Peter Tak Chief Executive Officer | Sold10b5-1 plan 2 parts | 280,245 | $11.28 average | $3.16M | 71% | Form 4 |
| Aug 17 | Seshu Tyagarajan Chief Technology Officer | Sold10b5-1 plan | 7,000 | $12.00 | 84K | 8.3% | Form 4 |
| Jun 29 | Seshu Tyagarajan Chief Technology Officer | Sold10b5-1 plan | 7,000 | $10.02 | 70K | 7.7% | Form 4 |
| Jun 29 | Francesca Barone Chief Scientific Officer | Sold10b5-1 plan | 23,447 | $10.06 | 236K | 23% | Form 4 |
| Feb 23 | Paul B Manning Director | Bought | 550,458 | $5.45 | $3M | 11% | Form 4 |
| Jul 28, 2025 | William Garrett Nichols Chief Medical Officer | Sold10b5-1 plan | 937 | $6.98 | 7K | 1.8% | Form 4 |
| Jun 30, 2025 | William Garrett Nichols Chief Medical Officer | Sold10b5-1 plan | 781 | $5.04 | 4K | 1.5% | Form 4 |
| Mar 18, 2025 – Mar 19, 2025 | Paul Peter Tak Chief Executive Officer | Sold10b5-1 plan 2 parts | 26,172 | $8.77 average | 230K | 10% | Form 4 |
| Mar 18, 2025 | William Garrett Nichols Chief Medical Officer | Sold10b5-1 plan | 45,316 | $8.76 | 397K | 46% | Form 4 |
| Mar 18, 2025 | Francesca Barone Chief Scientific Officer | Sold10b5-1 plan | 32,146 | $8.76 | 282K | 25% | Form 4 |
| Mar 17, 2025 | Seshu Tyagarajan Chief Technology Officer | Sold10b5-1 plan | 31,278 | $8.82 | 276K | 27% | Form 4 |
| Mar 17, 2025 | Charles Schoch See Remarks | Sold10b5-1 plan | 5,000 | $8.83 | 44K | 12% | Form 4 |
| Jan 15, 2025 | Seshu Tyagarajan Chief Technology Officer | SoldNo plan | 14,322 | $7.23 | 104K | 13% | Form 4 |
| Jan 15, 2025 | Francesca Barone Chief Scientific Officer | SoldNo plan | 13,534 | $7.23 | 98K | 11% | Form 4 |
| Jan 15, 2025 | Charles Schoch See Remarks | SoldNo plan | 9,511 | $7.23 | 69K | 18% | Form 4 |
| Jan 15, 2025 | Paul Peter Tak Chief Executive Officer | SoldNo plan | 21,704 | $7.23 | 157K | 7.9% | Form 4 |
| Jan 15, 2025 | William Garrett Nichols Chief Medical Officer | SoldNo plan | 10,428 | $7.23 | 75K | 12% | Form 4 |
| Jan 8, 2025 | Francesca Barone Chief Scientific Officer | SoldNo plan | 13,673 | $8.22 | 112K | 9.9% | Form 4 |
| Jan 8, 2025 | Charles Schoch See Remarks | SoldNo plan | 9,971 | $8.22 | 82K | 16% | Form 4 |
| Jan 8, 2025 | Paul Peter Tak Chief Executive Officer | SoldNo plan | 21,172 | $8.22 | 174K | 7.2% | Form 4 |
| Jan 8, 2025 | Seshu Tyagarajan Chief Technology Officer | SoldNo plan | 14,545 | $8.22 | 120K | 12% | Form 4 |
| Jan 8, 2025 | William Garrett Nichols Chief Medical Officer | SoldNo plan | 10,799 | $8.22 | 89K | 11% | Form 4 |
| Dec 16, 2024 | Paul B Manning Director | Bought 2 parts | 1,250,000 | $6.00 average | $7.5M | 43% | Form 4 |
| Nov 29, 2024 | Seshu Tyagarajan Chief Technology Officer | SoldNo plan | 20,392 | $4.56 | 93K | 14% | Form 4 |
| Nov 29, 2024 | Paul Peter Tak Chief Executive Officer | SoldNo plan | 48,847 | $4.56 | 223K | 14% | Form 4 |
| Nov 29, 2024 | William Garrett Nichols Chief Medical Officer | SoldNo plan | 13,935 | $4.56 | 64K | 12% | Form 4 |
| Nov 29, 2024 | Francesca Barone Chief Scientific Officer | SoldNo plan | 22,081 | $4.56 | 101K | 14% | Form 4 |
- Sep 10 – 1110b5-1 planPaul Peter TakChief Executive Officer · sold 280,245 at avg $11.28$3.16M71% of stake
- Aug 1710b5-1 planSeshu TyagarajanChief Technology Officer · sold 7,000 at $12.0084K8.3% of stake
- Jun 2910b5-1 planSeshu TyagarajanChief Technology Officer · sold 7,000 at $10.0270K7.7% of stake
- Jun 2910b5-1 planFrancesca BaroneChief Scientific Officer · sold 23,447 at $10.06236K23% of stake
- Feb 23Paul B ManningDirector · bought 550,458 at $5.45$3M11% of stake
- Jul 28, 202510b5-1 planWilliam Garrett NicholsChief Medical Officer · sold 937 at $6.987K1.8% of stake
- Jun 30, 202510b5-1 planWilliam Garrett NicholsChief Medical Officer · sold 781 at $5.044K1.5% of stake
- Mar 18, 2025 – Mar 19, 202510b5-1 planPaul Peter TakChief Executive Officer · sold 26,172 at avg $8.77230K10% of stake
- Mar 18, 202510b5-1 planWilliam Garrett NicholsChief Medical Officer · sold 45,316 at $8.76397K46% of stake
- Mar 18, 202510b5-1 planFrancesca BaroneChief Scientific Officer · sold 32,146 at $8.76282K25% of stake
- Mar 17, 202510b5-1 planSeshu TyagarajanChief Technology Officer · sold 31,278 at $8.82276K27% of stake
- Mar 17, 202510b5-1 planCharles SchochSee Remarks · sold 5,000 at $8.8344K12% of stake
- Jan 15, 2025No planSeshu TyagarajanChief Technology Officer · sold 14,322 at $7.23104K13% of stake
- Jan 15, 2025No planFrancesca BaroneChief Scientific Officer · sold 13,534 at $7.2398K11% of stake
- Jan 15, 2025No planCharles SchochSee Remarks · sold 9,511 at $7.2369K18% of stake
- Jan 15, 2025No planPaul Peter TakChief Executive Officer · sold 21,704 at $7.23157K7.9% of stake
- Jan 15, 2025No planWilliam Garrett NicholsChief Medical Officer · sold 10,428 at $7.2375K12% of stake
- Jan 8, 2025No planFrancesca BaroneChief Scientific Officer · sold 13,673 at $8.22112K9.9% of stake
- Jan 8, 2025No planCharles SchochSee Remarks · sold 9,971 at $8.2282K16% of stake
- Jan 8, 2025No planPaul Peter TakChief Executive Officer · sold 21,172 at $8.22174K7.2% of stake
- Jan 8, 2025No planSeshu TyagarajanChief Technology Officer · sold 14,545 at $8.22120K12% of stake
- Jan 8, 2025No planWilliam Garrett NicholsChief Medical Officer · sold 10,799 at $8.2289K11% of stake
- Dec 16, 2024Paul B ManningDirector · bought 1,250,000 at avg $6.00$7.5M43% of stake
- Nov 29, 2024No planSeshu TyagarajanChief Technology Officer · sold 20,392 at $4.5693K14% of stake
- Nov 29, 2024No planPaul Peter TakChief Executive Officer · sold 48,847 at $4.56223K14% of stake
- Nov 29, 2024No planWilliam Garrett NicholsChief Medical Officer · sold 13,935 at $4.5664K12% of stake
- Nov 29, 2024No planFrancesca BaroneChief Scientific Officer · sold 22,081 at $4.56101K14% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CADL
Held by ETFs
CADL is in 16 US ETFs. The largest of them, with CADL's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.18%of the fund
iShares Biotechnology ETFIBB0.04%of the fund
State Street SPDR S&P Kensho New Economies Composite ETFKOMP0.09%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.04%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.04%of the fund
Spot a number that looks wrong? Check it in CADL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CADL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.